Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · Real-Time Price · USD
135.73
-2.40 (-1.74%)
At close: Oct 29, 2025, 4:00 PM EDT
135.25
-0.48 (-0.35%)
After-hours: Oct 29, 2025, 5:24 PM EDT
Jazz Pharmaceuticals Employees
Jazz Pharmaceuticals had 2,800 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
2,800
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$1,459,534
Profits / Employee
-$144,586
Market Cap
8.23B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2,800 | 0 | - |
| Dec 31, 2023 | 2,800 | 0 | - |
| Dec 31, 2022 | 2,800 | -400 | -12.50% |
| Dec 31, 2021 | 3,200 | 1,260 | 64.95% |
| Dec 31, 2020 | 1,940 | 320 | 19.75% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
JAZZ News
- 1 day ago - Jazz Pharmaceuticals Appoints Ted W. Love, M.D. - PRNewsWire
- 7 days ago - Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 5, 2025 - PRNewsWire
- 8 days ago - Iambic Announces Research Collaboration with Jazz Pharmaceuticals for IAM1363 and Zanidatamab Combination Cohort in HER2-Positive Breast Cancer - Business Wire
- 12 days ago - 3 Small Cap Stocks To Play As The Bantamweights Break Out On Wall Street - Benzinga
- 26 days ago - FDA Approves Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer - PRNewsWire
- 27 days ago - US FDA approves Jazz Pharma's therapy for lung cancer - Reuters
- 5 weeks ago - Jazz Pharmaceuticals Announces Promising Xywav Data: Why I Assign A BUY Rating - Seeking Alpha
- 5 weeks ago - Jazz Pharmaceuticals Showcases Phase 4 Data Demonstrating Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Effects and Real-World Evidence at World Sleep and Psych Congresses - PRNewsWire